The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Uniseal, Inc.
Advised LG Chem, a global diversified chemicals manufacturer based in South Korea, on the acquisition of Uniseal, a US-based supplier of sealants and adhesives to leading automotive manufacturers
Nihon Nohyaku Co., Ltd.
Advised ADEKA Corporation, a global chemical manufacturer, on the acquisition of 51% stake of Nihon Nohyaku via the combination of the Tender Offer and Capital Injection
Martabe gold and silver mine
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
Park Electrochemical (Electronics Business)
Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.
35% of Sabine Oil & Gas’ interest in oil and gas properties in East Texas
Advised Osaka Gas, a Japanese utility, on the acquisition of 35% of Sabine Oil & Gas’s interest in oil and gas properties located primarily in Harrison and Panola Counties, Texas
Frutarom
Advised IFF, a leading innovator of specialty ingredients, on its acquisition of Frutarom, creating a global leader in Taste, Scent and Nutrition
Yakult
Advised Danone, a leading global food & beverage company, on renewing its strategic partnership with Yakult, a global leader in probiotic beverages, as well as the sale of part of its stake in Yakult
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Inenco Group Pty Ltd
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
US rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
Sewells Group
Advised WorldMark on the sale of Sewells Group to MSX International, a global provider of outsourced business solutions. Sewells, headquartered in Shanghai, is a leading provider of automotive dealership development services across Asia Pacific, Africa and the Middle East
COOEC Fluor Heavy Industries Co., Ltd.
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
WEGU Holding GmbH
Advised the shareholders of WEGU Holding GmbH, a German provider of anti-vibration solutions and light-weight components for the automotive and truck industries, on the sale of the Company to Anhui Zhongding Sealing Parts, a Chinese listed company that makes and sells rubber sealing parts and other rubber products
Nuplex Industries’ Specialties and Masterbatch businesses
Advised Nuplex Industries, a dual listed (ASX/NZX) global manufacturer, developer and distributor of resins and additives, on the sale of its specialty chemicals and masterbatch businesses to CHAMP Private Equity, a leading Australian private equity firm
Modern Star Pty Ltd
Advised Modern Star, Australia and New Zealand’s #1 supplier of education resources and educational toys, on the sale of 90% of its shares to Navis Capital, a leading private equity group focused on investments in South and Southeast Asia
Publications International, Ltd. Children’s Division
Advised Publications International, a leading consumer book publisher, on the sale of its Children’s Division to Jiangsu Phoenix Publishing and Media Corporation Limited